Cytokine · 2018
Inbred mouse strains differentially susceptible to Leishmania donovani infection differ in their immune cell metabolism.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bodhale Neelam Prakash, Pal Subhashis, Kumar Sunil, Chattopadhyay Debprasad, Saha Bhaskar, Chattopadhyay Naibedya, Bhattacharyya Maitree
Аннотация
Leishmania donovani is a protozoan parasite that infects mammalian macrophages, wherein the parasite resides and replicates as amastigotes, inflicting the potentially fatal disease visceral leishmaniasis. The disease is characterized by severe immunosuppression and hypocholesterolemia implying metabolic changes in L. donovani infection; whether such metabolic changes are also linked to susceptibility to the infection is not known. Herein, four inbred mouse strains were first characterized for their resistance or susceptibility profile to L. donovani infection. It was observed that these four mouse strains were differentially susceptible to L. donovani infection. Splenic expression of four key cytokines- IL-10, IL-12, IFN-γ and IL-4- revealed that the differential susceptibility of these four mouse strains to L. donovani was partially associated with these cytokines. The association was further correlated with the expression of different enzymes of the glycolytic pathway in the spleen of these L. donovani-infected mice. Thus, the observations reported here suggest an association between host metabolism, cytokine secretion profile and L. donovani susceptibility. As the chemotherapeutic choices are extremely limited and a vaccine for human use is yet to be discovered for the neglected tropical disease that is prevalent in 88 countries affecting 320 million people, this metabolic study is a significant research area that has potentials to develop a new target for anti-leishmanial chemotherapy.